Image

Breaking News

Featured image for “ESMO: TIL therapy improves on Yervoy in melanoma trial”
09/13/2022

ESMO: TIL therapy improves on Yervoy in melanoma trial

(NEWS PROVIDED BY  Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
Blog - Melanoma360
Breaking News
Featured image for “Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors”
09/12/2022

Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors

(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…
Blog - Melanoma360
Breaking News
Featured image for “Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma”
09/11/2022

Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma

Neoadjuvant IO Boosts High-Risk Melanoma EFS Results from the phase 2 SWOG S1801 study show that for patients given pembrolizumab…
Blog - Melanoma360
Breaking News
Featured image for “Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag”
07/22/2022

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag

(reprint from Business Wire, published: July 22, 2022) Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody…
Blog - Melanoma360
Breaking News
Featured image for “Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma”
06/06/2022

Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma

(reprint from Biospace, published: Jun 03, 2022) Immunocore announcesclinical trial collaboration with Sanofito evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2,in combination with KIMMTRAK® in patients with metastatic cutaneous…
Blog - Melanoma360
Breaking News
Featured image for “Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II Melanoma”
06/05/2022

Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II Melanoma

(reprint from Targeted Oncology, published: Jun 05, 2022) Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II…
Blog - Melanoma360
Breaking News
Featured image for “FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
03/19/2022

FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

CONTACT: Samantha Guild President AIM at Melanoma Foundation 916/206-6100 SGuild@AIMatMelanoma.org March 19, 2022 (Richmond, California) Yesterday, Bristol Myers Squibb announced…
Blog - Melanoma360
Breaking News
Featured image for “FDA Approves KIMMTRAK (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma”
01/26/2022

FDA Approves KIMMTRAK (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma

January 26, 2022 (Richmond, California) Earlier today, Immunocore announced that the U.S. Food and Drug Administration (FDA) has approved KIMMTRAK…
Blog - Melanoma360
Breaking News
Featured image for “FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients”
12/04/2021

FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients

  December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA”
10/07/2021

Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA

October 1, 2021 Kristi Rosa REPOST from OncLive The European Medicines Agency has validated its marketing authorization application for the…
Blog - Melanoma360
Breaking News
Melanoma Research
09/13/2022

ESMO: TIL therapy improves on Yervoy in melanoma trial

(NEWS PROVIDED BY  Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
Featured image for “ESMO: TIL therapy improves on Yervoy in melanoma trial”
Blog - Melanoma360
 | 
Breaking News
09/12/2022

Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors

(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…
Featured image for “Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors”
Blog - Melanoma360
 | 
Breaking News
09/11/2022

Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma

Neoadjuvant IO Boosts High-Risk Melanoma EFS Results from the phase 2 SWOG S1801 study show that for patients given pembrolizumab…
Featured image for “Pembrolizumab in the Neoadjuvant Setting Benefits EFS in High-Risk Melanoma”
Blog - Melanoma360
 | 
Breaking News
07/22/2022

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag

(reprint from Business Wire, published: July 22, 2022) Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody…
Featured image for “Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag”
Blog - Melanoma360
 | 
Breaking News
06/06/2022

Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma

(reprint from Biospace, published: Jun 03, 2022) Immunocore announcesclinical trial collaboration with Sanofito evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2,in combination with KIMMTRAK® in patients with metastatic cutaneous…
Featured image for “Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma”
Blog - Melanoma360
 | 
Breaking News
06/05/2022

Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II Melanoma

(reprint from Targeted Oncology, published: Jun 05, 2022) Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II…
Featured image for “Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II Melanoma”
Blog - Melanoma360
 | 
Breaking News
03/19/2022

FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

CONTACT: Samantha Guild President AIM at Melanoma Foundation 916/206-6100 SGuild@AIMatMelanoma.org March 19, 2022 (Richmond, California) Yesterday, Bristol Myers Squibb announced…
Featured image for “FDA Approves Opdualag (nivolumab and relatlimab-rmbw) Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
Blog - Melanoma360
 | 
Breaking News
01/26/2022

FDA Approves KIMMTRAK (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma

January 26, 2022 (Richmond, California) Earlier today, Immunocore announced that the U.S. Food and Drug Administration (FDA) has approved KIMMTRAK…
Featured image for “FDA Approves KIMMTRAK (tebentafusp-tebn) for the Treatment of Unresectable or Metastatic Uveal Melanoma”
Blog - Melanoma360
 | 
Breaking News
12/04/2021

FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients

  December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
Featured image for “FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
10/07/2021

Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA

October 1, 2021 Kristi Rosa REPOST from OncLive The European Medicines Agency has validated its marketing authorization application for the…
Featured image for “Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research